Search

Your search keyword '"Misset, Jean-Louis"' showing total 216 results
Start Over Author "Misset, Jean-Louis"
216 results on '"Misset, Jean-Louis"'

11. Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen

Author

Bertheau, Philippe, Turpin, Elisabeth, Rickman, David S., Espie, Marc, De Renies, Aurelien, Feugeas, Jean-Paul, Plassa, Louis-Francois, Soliman, Hany, Varna, Mariana, De Roquancourt, Anne, Lehmann-Che, Jacqueline, Beuzard, Yves, Marty, Michel, Misset, Jean-Louis, Janin, Anne, and De The, Hugues

Subjects
Epirubicin -- Health aspects, Cyclophosphamide -- Health aspects, Breast cancer -- Care and treatment
Abstract

ABSTRACT Background In breast cancers, only a minority of patients fully benefit from the different chemotherapy regimens currently in use. Identification of markers that could predict the response to a [...]

Published
2007

26. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial

Author

Levi, Francis A., Zidani, Rachid, Vannetzel, Jean-Michel, Perpoint, Bruno, Focan, Christian, Faggiuolo, Roberto, Chollet, Philippe, Garufi, Carlo, Itzhaki, Moshe, Dogliotti, Luigi, Iacobelli, Stefano, Adam, Rene, Kunstlinger, Francis, Gastiaburu, Julio, Bismuth, Henri, Jasmin, Claude, and Misset, Jean-Louis

Subjects
Colorectal cancer, Chemotherapy, Combination -- Dosage and administration, Metastasis, Antineoplastic agents -- Dosage and administration, Health
Abstract

Background: In a previous phase 11 trial, circadian (chronomodulated) delivery of fluorouracil (5-FU), folinic acid (FA; leucovorin), and oxaliplatin (l-OHP; a new platinum complex with no renal and minor hematologic toxic effects) produced an objective response rate of 58% in 93 patients with metastatic colorectal cancer. Purpose: To determine whether chronomodulated drug delivery affects therapeutic activity, we again tested this regimen in another trial in patients with previously untreated metastatic colorectal cancer, this time comparing chronomodulated with constantrate drug delivery. Methods: Seven European centers participated in this trial. Ninety-two patients with metastatic colorectal cancer were enrolled and assigned to a treatment schedule by central randomization. Treatment courses consisted of the daily administration of 5-FU (600 mg/[m.sup.2] per day), FA (300 mg/[m.sup.2] per day), and l-OHP (20 mg/[m.sup.2] per day) for 5 days and were repeated every 21 days (16-day intermission) in ambulatory patients with the use of a programmable in-time pump. Drug delivery was kept constant over a 5-day period in schedule A (47 patients). It was chronomodulated in schedule B (maximum delivery of 5-FU and FA infusions at 0400 hours and maximum delivery of l-OHP at 1600 hours; 45 patients). A risk of partial chemical inactivation of l-OHP by its 2-hour exposure to the basic pH of the 5-FU solution in the catheter was documented in schedule A. Results: Severe stomatitis (grade 3 or 4, World Health Organization [WHO] grading system), the dose-limiting toxic effect of 5-FU, occurred in five times as many patients on schedule A than on schedule B (89% versus 18%; [[chi.sup.2]] = 46; P < .001). The cumulative dose-limiting toxicity of schedule B was peripheral sensitive neuropathy (WHO grade 2). This side effect was reversible following l-OHP withdrawal. Higher doses of 5-FU were administered in schedule B (median: 700 mg/[m.sup.2] per day) compared with schedule A (median: 500 mg/[m.sup.2] per day) (P < .0001; Mann-Whitney U test). On schedule B, 24 of 45 patients (53%; 95% confidence interval [CI] = 38%-68%) exhibited an objective response compared with 15 of 47 patients (32%; 95% CI = 18%-46%) on schedule A ([[chi.sup.2]] = 4.3; P = .038). The median progression-free survival was, respectively, 11 and 8 months (P = .19; logrank). The median survival was 19 months (95% CI = 14.8-23.2) on schedule B and 14.9 months (95% CI = 12.1-17.8) on schedule A (P = .03; logrank). Conclusion: This ambulatory treatment modality was both more effective and less toxic if drug delivery was chronomodulated rather than constant over time. Implication: The respective roles of l-OHP dose and schedule and circadian peak time of drug delivery are being investigated with regard to the high activity of this three-drug, chronomodulated chemotherapeutic regimen.

Published
1994

27. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump: high antitumor effectiveness against metastatic colorectal cancer

Author

Levi, Francis, Misset, Jean-Louis, Brienza, Silvano, Adam, Rene, Metzger, Gerard, Itzakhi, Moshe, Caussanel, Jeanne-Pierre, Kunstlinger, Francis, Lecouturier, Sylvie, Descorps-Declere, Adrien, Jasmin, Claude, Bismuth, Henri, and Reinberg, Alain

Subjects
Pharmacology -- Usage, Fluorouracil -- Evaluation, Leucovorin -- Evaluation, Colorectal cancer, Infusion therapy -- Methods, Health
Published
1992

29. Éditorial

Author

Beaufils, François, primary, Misset, Jean-Louis, additional, and Poisson, Dominique, additional

Published
2016
Full Text
View/download PDF

30. A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on letrozole

Author

Gunzer, Katharina, primary, Joly, Florence, additional, Ferrero, Jean-Marc, additional, Gligorov, Joseph, additional, de Mont-Serrat, Helene, additional, Uttenreuther-Fischer, Martina, additional, Pelling, Katy, additional, Wind, Sven, additional, Bousquet, Guilhem, additional, and Misset, Jean-Louis, additional

Published
2016
Full Text
View/download PDF

34. Lenalidomide (REV) in asymptomatic late recurrent ovarian cancer (ROC) patients with increasing CA 125: A GINECO phase II trial.

Author

Selle, Frédéric, primary, Ray-Coquard, Isabelle, additional, Sevin, Emmanuel, additional, Mari, Véronique, additional, Berton-Rigaud, Dominique, additional, Bourgeois, Hugues Pierre, additional, Dohollou, Nadine, additional, Fabbro, Michel, additional, Floquet, Anne, additional, Lesoin, Anne, additional, Lortholary, Alain, additional, Hardy-Bessard, Anne-Claire, additional, Misset, Jean-Louis, additional, Mouret-Reynier, Marie-Ange, additional, and Pujade-Lauraine, Eric, additional

Published
2012
Full Text
View/download PDF

35. Characterization and multiparameter analysis of visual adverse events in irofulven single-agent phase I and II trials

Author

UCL - MD/CHIR - Département de chirurgie, Raymond, Eric, Kahatt, Carmen, Rigolet, Marie Hélène, Sutherland, William, Lokiec, François, Alexandre, Jérôme, Tombal, Bertrand, Elman, Michael, Lee, Michael S., MacDonald, John R., Cullen, Michael, Misset, Jean-Louis, Cvitkovic, Esteban, UCL - MD/CHIR - Département de chirurgie, Raymond, Eric, Kahatt, Carmen, Rigolet, Marie Hélène, Sutherland, William, Lokiec, François, Alexandre, Jérôme, Tombal, Bertrand, Elman, Michael, Lee, Michael S., MacDonald, John R., Cullen, Michael, Misset, Jean-Louis, and Cvitkovic, Esteban

Abstract

Purpose: Irofulven (6-hydroxymethylacylfulvene) is a novel agent, derived from illudin S, with potent apoptotic effects in preclinical models. In the Phase I trial evaluating intermittent weekly schedules, visual symptoms were dose limiting. The aim of this analysis was to better characterize the visual adverse events of irofulven and provide treatment guidelines. Experimental Design: Clinical data from 277 patients entered in single-agent Phase I to II clinical trials who received irofulven on days 1 and 15 every 4 weeks; days 1, 8, and 15 every 4 weeks; or days 1 and 8 every 3 weeks were included in this multiparameter analysis. Results: Overall, 74 patients (27%) experienced visual symptoms. The most frequently reported symptoms were flashing lights (12% of patients), blurred vision (9%), and photosensitivity (8%). Grade 3 toxicity was observed in 12 patients (4%). The incidence and severity of visual events were dose dependent, with no grade 3 visual events occurring at doses less than or equal to 0.50 mg/kg and grade 1 to 2 events in only 12% and 8% of patients, at doses of less than or equal to 0.50 mg/kg and less than or equal to 20 mg/m(2), respectively. Grade I to 2 toxicity was reversible in most patients. Abnormal electroretinogram and abnormal visual fields were noted after irofulven treatment in 24 of 39 patients (62%) and 15 of 26 patients (58%), respectively. All but 1 patient who had electroretinogram assessment received doses > 0.50 mg/kg. Clinical examination and visual field assessment were found to be better correlated with symptoms and appear to be more appropriate for surveillance of irofulven retinal symptoms than electroretinograms. Conclusions: On the basis of retained antitumor activity and reversibility of grade 1 and 2 visual symptoms at lower doses, it appears that an irofulven dose of less than or equal to 0.50 mg/kg or less than or equal to 20 mg/m(2), not to exceed 50 mg in a single dose, given as a 30-minute infusion on days 1 and 8

Published
2004

37. Le cancer du sein sans envahissement ganglionnaire. Au-delà des consensus internationaux : une approche pragmatique

Author

Penault-Llorca, Frédérique, primary, Coeffic, David, additional, Delozier, Thierry, additional, Dohollou, Nadine, additional, Freyer, Gilles, additional, Gligorov, Joseph, additional, Hardy-Bessard, Anne-Claire, additional, Jacot, William, additional, Misset, Jean-Louis, additional, Nabholtz, Jean-Marc, additional, Petit, Thierry, additional, Spielmann, Marc, additional, and Namer, Moïse, additional

Published
2011
Full Text
View/download PDF

44. Efficacy of Trastuzumab in Routine Clinical Practice and After Progression for Metastatic Breast Cancer Patients: The Observational Hermine Study

Author

Extra, Jean-Marc, primary, Antoine, Eric C., additional, Vincent-Salomon, Anne, additional, Delozier, Thierry, additional, Kerbrat, Pierre, additional, Bethune-Volters, Anne, additional, Guastalla, Jean-Paul, additional, Spielmann, Marc, additional, Mauriac, Louis, additional, Misset, Jean-Louis, additional, Serin, Daniel, additional, Campone, Mario, additional, Hebert, Christophe, additional, Remblier, Céline, additional, Bergougnoux, Loïc, additional, Campana, Frank, additional, and Namer, Moïse, additional

Published
2010
Full Text
View/download PDF

46. Prospective Multicenter Study for Evaluating Cognitive Disorders in Hematology-Oncology: A Pilot Study of 118 Patients

Author

Rossi, Jean François, primary, Laurier, Laurence, primary, Misset, Jean-Louis, primary, Spaeth, Dominique, primary, Uwer, F., primary, Soubeyran, Pierre, primary, Largiller, Remy, primary, Metges, Jean-Philippe, primary, Blay, Jean- Yves, primary, Attal, Michel, primary, Facon, Thierry, primary, Hermine, Olivier, primary, Bugat, Roland, primary, Spano, Jean-Philippe, primary, Cals, Laurent, primary, Cure, Hervé, primary, Atlan, Dan, primary, and Gjoklaj, Mario, primary

Published
2008
Full Text
View/download PDF

47. Effect of 18F-FDG PET/CT Imaging in Patients With Clinical Stage II and III Breast Cancer

Author

Groheux, David, primary, Moretti, Jean-Luc, additional, Baillet, Georges, additional, Espie, Marc, additional, Giacchetti, Sylvie, additional, Hindie, Elif, additional, Hennequin, Christophe, additional, Vilcoq, Jacques-Robert, additional, Cuvier, Caroline, additional, Toubert, Marie-Elisabeth, additional, Filmont, Jean-Emmanuel, additional, Sarandi, Farid, additional, and Misset, Jean-Louis, additional

Published
2008
Full Text
View/download PDF

48. Oxaliplatin clinical activity: A review

Author

Misset, Jean Louis, Bleiberg, Harry, Sutherland, William, Bekradda, Mohamed, Cvitkovic, Esteban, Misset, Jean Louis, Bleiberg, Harry, Sutherland, William, Bekradda, Mohamed, and Cvitkovic, Esteban

Abstract

Oxaliplatin (Eloxatin(TM)), a recently developed third-generation cisplatin analogue with a 1,2-diaminocyclohexane (DACH) carrier ligand, has displayed preclinical and clinical activity in a wide variety of tumour types. Synergistic with 5-FU in colorectal cancer (CRC), the combination has proven efficacy in 5-FU-resistant advanced disease and in previously untreated CRC, as demonstrated in controlled phase III trials, while evaluation in the adjuvant setting is ongoing. Due to its excellent safety profile, its unique mechanism of action and lack of cross-resistance with other active agents in CRC, oxaliplatin has also been combined with CPT-11 and Raltitrexed with promising results. Trials in pretreated and untreated advanced ovarian cancer (AOC), as a single agent or in combination with cisplatin, cyclophosphamide or paclitaxel, indicate a yet to be defined role in AOC and confirm its lack of cross-resistance with cis/carboplatin. Clinical investigations of single agent and combination therapies in breast, lung, prostate and germ-cell carcinomas, non-Hodgkin's lymphoma and malignant mesothelioma are being pursued. While the role of oxaliplatin in medical oncology is yet to be fully defined, it appears to be an important new anticancer agent. Copyright (C) 2000 Elsevier Science Ireland Ltd., SCOPUS: re.j, info:eu-repo/semantics/published

Published
2000

50. Exquisite Sensitivity of TP53 Mutant and Basal Breast Cancers to a Dose-Dense Epirubicin−Cyclophosphamide Regimen

Author

Bertheau, Philippe, primary, Turpin, Elisabeth, additional, Rickman, David S, additional, Espié, Marc, additional, de Reyniès, Aurélien, additional, Feugeas, Jean-Paul, additional, Plassa, Louis-François, additional, Soliman, Hany, additional, Varna, Mariana, additional, de Roquancourt, Anne, additional, Lehmann-Che, Jacqueline, additional, Beuzard, Yves, additional, Marty, Michel, additional, Misset, Jean-Louis, additional, Janin, Anne, additional, and de Thé, Hugues, additional

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results